Repligen has announced positive results from the Phase 1 study of RG3039, a small molecule drug candidate for the treatment of spinal muscular atrophy (SMA).

The Phase 1 trial is a blinded ascending single dose study that involved 32 healthy volunteers to investigate the pharmacokinetic (PK) and safety profile of RG3039.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The study data demonstrates that RG3039 was well-tolerated at all doses administered and also reported evidence of a dose-related drug response resulting in 90% inhibition of the target enzyme.

Repligen president and chief executive officer Walter Herlihy said that the safety and PK outcomes from the Phase 1 study of RG3039 are encouraging, and the company looks forward to initiating the next steps for the drug candidate in alignment with guidance from the US Food and Drug Administration.

"The agency has previously granted Orphan Drug and Fast Track designations to RG3039, in recognition of the unmet medical need that exists for patients with SMA and the urgency to advance a treatment for this devastating disease," Herlihy added.

See Also:

RG3039 is an orally bioavailable small molecule inhibitor of an RNA processing enzyme called DcpS, and has been shown to increase production of survival motor neuron (SMN) protein in cells derived from SMA patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Previous preclinical studies also showed that administration of RG3039 resulted in considerable improvements in survival and motor behaviour, as well as increased maximum body weight in severe SMA mice.

The Phase I study of RG3039 has been partially supported by a grant from the Muscular Dystrophy Association (MDA).

RG3039 has been granted orphan drug and fast track designations in the US as well as orphan medicinal product designation in the EU for treating SMA.

Spinal muscular atrophy is an autosomal recessive neuromuscular disease in which a defect in the SMN1 gene results in low levels of SMN protein, thereby leading to progressive damage to motor neurons.